Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B virus-specific cytotoxic T lymphocytes
- Development stage
- Unknown
- Lead developer
- Three Gorges Hospital of Chongqing University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Hepatitis B virus-specific cytotoxic T lymphocytes is an autologous adoptive cell therapy developed by Chongqing Three Gorges Central Hospital for the treatment of chronic hepatitis B. The therapy involves the ex vivo expansion and activation of a patient's own T cells using specific HBV antigens, such as HBsAg, HBcAg, and HBeAg. These sensitized cytotoxic T lymphocytes (CTLs) are then re-infused into the patient, where they are designed to recognize and lyse HBV-infected hepatocytes that present viral peptides on their surface via MHC class I molecules. This approach aims to overcome the T-cell exhaustion and immune tolerance typically observed in chronic HBV infection, thereby reducing viral load and potentially achieving a functional cure.
- Other names
- HBV-specific CTLsHBV-CTL
02
Targets
Hepatitis B virus peptide–Major Histocompatibility Complex class I
Beyond the preview
Go deeper on hepatitis B virus-specific cytotoxic T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B virus-specific cytotoxic T lymphocytes.